Abstract
BackgroundThe efficacy and safety of etanercept (ETN) has been demonstrated in patients with juvenile idiopathic arthritis (JIA) from 4 years, although more data are needed regarding the population under 4...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
